Cost effectiveness of a 21-valent pneumococcal conjugate vaccine in adults: A systematic review of economic evaluations
Open Access
- 12 February 2025
- journal article
- review article
- Published by Infectious Disease and Control Branch (IDPCB) - Public Health Agency of Canada in Canada Communicable Disease Report
- Vol. 51 (2/3) , 84-91
Abstract
In July 2024, Health Canada authorized a 21-valent pneumococcal conjugate vaccine (Pneu-C-21) for use in adults. To conduct a systematic review of the cost-effectiveness of Pneu-C-21 for preventing pneumococcal disease in adults. We conducted a systematic search of the literature and National Immunization Technical Advisory Groups’ websites on July 3, 2024. We included economic evaluations that assessed Pneu-C-21 as a vaccination strategy among adults aged 18 years and older. Costs were adjusted to 2023 Canadian dollars. We identified 10 studies in our search, five of which were summarized in our review. No economic evaluations were conducted in Canada. All economic evaluations used static cohort models and incorporated indirect effects from paediatric pneumococcal conjugate vaccination in primary or sensitivity analyses. Although incremental cost-effectiveness ratios were heterogeneous across included economic evaluations, overall, they qualitatively identified the same vaccination strategies as optimal within the given age and risk groups. Pneu-C-21 is likely to be cost-effective in adults aged 65 years and older and adults under the age of 65 years with specific high risk conditions. Pneu-C-21 is likely to be cost-effective in adults within specific age and risk groups. The applicability of the included economic evaluations to adults living in Canada is limited because the serotype-specific incidence of pneumococcal disease and the impact of indirect effects from pediatric vaccination varies by region and over time.Keywords
This publication has 13 references indexed in Scilit:
- Cost-effectiveness of an in-development adult-formulated 21-valent pneumococcal conjugate vaccine in US adults aged 50 years or olderVaccine, 2024
- Higher-valency pneumococcal conjugate vaccines in older adults, taking into account indirect effects from childhood vaccination: a cost-effectiveness study for the NetherlandsBMC Medicine, 2024
- International Prescription Drug Price Comparisons: Estimates Using 2022 Data2024
- Cost-effectiveness of an in-development adult-formulated pneumococcal vaccine in older US adultsVaccine, 2023
- Historical Population-Level Impact of Infant 13-Valent Pneumococcal Conjugate Vaccine (PCV13) National Immunization Programs on Invasive Pneumococcal Disease in Australia, Canada, England and Wales, Israel, and the United StatesInfectious Diseases and Therapy, 2023
- A New Pneumococcal Capsule Type, 10D, is the 100th Serotype and Has a Large cps Fragment from an Oral StreptococcusmBio, 2020
- Streptococcus pneumoniae: transmission, colonization and invasionNature Reviews Microbiology, 2018
- Conducting systematic reviews of economic evaluationsJBI Evidence Implementation, 2015
- Dynamic Transmission Modeling: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-5Value in Health, 2012
- Economic evaluations in the critical care literatureCritical Care Medicine, 1996